Abstract
Immunodeficient mouse models are helping to advance the field of oncology. A new model on the market, the B6;129-Rag2tm1Fwa IL2rgtm1Rsky /DwlHsd (R2G2) knockout mouse, lacks responsiveness to common gamma chain cytokines, including IL-2, IL-4, IL-7, IL-9 and IL-15. In addition, this model exhibits defects in lymphoid development and so lacks mature lymphocytes of the B, T, and natural killer (NK) cell lineages. Herein we describe growth and take rate of a few tumor cell line xenografts in the R2G2 immunodeficient mouse model. The cell line xenografts studied include multiple myeloma, pancreatic, Burkitt's lymphoma, ovarian, and breast cancer. Multiple myeloma (MM1.S cells) were inject via the tail vein at 50 × 104 cells per mouse. IVIS imaging was used to measure tumor burden of luciferase transfected cells. The pancreatic cancer (BxPC-3 cells) was injected subcutaneously at 1 × 106 and tumor volume was measured weekly. Burkitt's lymphoma (RAJI) cells, ovarian (A2780) cancer cells, and breast (T47D, MDA-MB-231, and MCF-7) cancer cells were implanted subcutaneously at 1 × 106 cells in both flanks of five mice each. Tumor volume and body weight was measured twice weekly for five weeks. These data provide evidence that the R2G2 mouse model is a valuable tool for oncology programs including cell line tumor models research, with high take rates and quick growth of allogeneic models. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
